Dr. David Maggs is the Vice President, Medical Affairs, BD Technologies and Innovation (BDTI) based in Research Triangle Park, NC. Dr. Maggs joined BD in March 2019 and is responsible for providing medical, scientific, technical and customer-focused leadership for the BDTI R&D portfolio. He has also taken on interim leadership of Medical Affairs for the North America Region.
Dr. Maggs is a board-certified endocrinologist and most recently served as Chief Medical Officer of Fractyl Laboratories and, prior to this, at GI Dynamics. Previous to this time, he spent more than a decade at Amylin Pharmaceuticals, where he held positions of increasing responsibility, serving as Vice President Medical Research and Development. He was integral to the development and commercialization of the company’s peptide therapeutic portfolio and he led numerous innovative collaborations directly engaged with the global diabetes and endocrine community. Prior to his Amylin tenure, David served as Director, Diabetes and Metabolism, for Parke-Davis and then Pfizer.
Dr. Maggs is currently an Adjunct Faculty Member of the School of Medicine at The University of Texas Health Science Center and was previously an Assistant Clinical Professor at the Yale School of Medicine and completed fellowships at the University of Nottingham and at the Yale School of Medicine. He completed his original medical training and received his MBBS from Guys Hospital, University of London, and he is a Fellow of the Royal College of Physicians in London.
